Research Topics
Species | S SleijferSummaryAffiliation: Erasmus MC Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Thalidomide in solid tumours: the resurrection of an old drugStefan Sleijfer
Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Groene Hilledijk 301, EA Rotterdam 3075, The Netherlands
Eur J Cancer 40:2377-82. 2004..This Review focuses on the application of thalidomide and its derivatives in solid tumours, the mechanisms underlying their anti-tumour effects, and their potential to be applied in combination with other anti-tumour agents...- Circulating tumour cell detection on its way to routine diagnostic implementation?Stefan Sleijfer
Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Clinic, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Eur J Cancer 43:2645-50. 2007..This review addresses CTCs, and in particular, technical issues concerning their detection, clinical results obtained so far, and future perspectives... 
Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatmentStefan Sleijfer
Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands
Nat Clin Pract Oncol 5:102-11. 2008..This Review discusses the pathogenesis of GIST, treatment strategies, mechanisms accounting for drug resistance, and potential future perspectives...- With a little help from small friends: Enhanced chemotherapeutic effects with imatinibStefan Sleijfer
Eur J Cancer 42:808-10. 2006 - Practical aspects of managing gastrointestinal stromal tumorsStefan Sleijfer
Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
Clin Colorectal Cancer 6:S18-23. 2006..This review addresses several aspects of the current management of GIST as well as some novel developments... 
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG studyS Sleijfer
Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Br J Cancer 107:639-45. 2012....- Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard careStefan Sleijfer
Department of Medical Oncology, Daniel den Hoed Cancer Centre, Erasmus University Medical Centre, Rotterdam, The Netherlands
Oncologist 10:833-41. 2005..This review also focuses on these and other strategies that will hopefully lead to better out comes in this disease entity in the near future... - Gynaecological sarcomasStefan Sleijfer
Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands
Curr Opin Oncol 19:492-6. 2007..To review gynaecological sarcomas, their management and future perspectives... - Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatmentStefan Sleijfer
Department of Medical Oncology, Erasmus University Medical Centre, Daniel den Hoed Cancer Centre, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Oncologist 12:719-26. 2007.... - Angiogenesis inhibition in non-GIST soft tissue sarcomasStefan Sleijfer
Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Oncologist 13:1193-200. 2008..This review discusses the currently available evidence supporting a role for angiogenic factors in the pathogenesis of STSs and the first preliminary study results obtained with angiogenesis inhibitors... - Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 620Stefan Sleijfer
Dept of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
J Clin Oncol 27:3126-32. 2009..7%). CONCLUSION Pazopanib is well tolerated in patients with relapsed, advanced STS and demonstrates interesting activity that warrants additional study in patients with leiomyosarcomas, synovial sarcomas, and other STS types... - Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and TrStefan Sleijfer
Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
Eur J Cancer 46:72-83. 2010..As ifosfamide is frequently applied in first line systemic therapy, we aimed to establish prognostic and predictive factors for outcome to ifosfamide-based therapy... - The potential of statins as part of anti-cancer treatmentStefan Sleijfer
Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Eur J Cancer 41:516-22. 2005..Nevertheless, the interesting pre-clinical anti-tumour activity of statins combined with a favourable toxicity profile warrant their further development as anti-tumour agents, in particular as part of multi-drug regimens... - Side effects of interferon-alpha therapyStefan Sleijfer
Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, P O Box 5201, 3008, Rotterdam, AE, The Netherlands
Pharm World Sci 27:423-31. 2005..This review addresses the toxicity profile of IFN-alpha, the presumed pathophysiology of the different side effects and the strategies to handle these... - The price of success: cost-effectiveness of molecularly targeted agentsS Sleijfer
Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Clin Pharmacol Ther 85:136-8. 2009..It seems that establishment of cost-effectiveness is complex but is determined for the most part by the cost of drug acquisition and the drug's efficacy. This article examines the cost-effectiveness of molecularly targeted drugs... - A new approach for rapid and reliable enumeration of circulating endothelial cells in patientsJ Kraan
Department of Medical Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, Netherlands
J Thromb Haemost 10:931-9. 2012..Mature circulating endothelial cells (CECs) are surrogate markers of endothelial damage/dysfunction. A lack of standardized assays and consensus on CEC phenotype has resulted in a wide variation of reported CEC numbers (4-1300 per mL)... - Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignanciesP Hamberg
Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Br J Cancer 102:1699-706. 2010..This study aimed to define the maximally tolerated dose (MTD) of sunitinib combined with two different infusion schedules of ifosfamide... - The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomasMetin Tascilar
Department of Medical Oncology, Erasmus University Medical Center Rotterdam Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075EA Rotterdam, The Netherlands
Oncologist 12:1351-60. 2007..Furthermore, this review focuses on the anticipated growing role of ifosfamide in the development of new treatment strategies... - Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysisAmir Mearadji
Department of Surgical Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Anticancer Drugs 19:607-12. 2008..For patients with metastatic GIST, the role of surgery remains less clear. Loss or decrease of CD117 expression in the resected specimen after imatinib treatment may be associated with disease recurrence... - Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxelM H Strijbos
Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
Eur J Cancer 46:2027-35. 2010..Additionally, we combined these markers with circulating tumour cells (CTCs) to construct a predictive nomogram for treatment outcome... - It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignanciesIngrid A Boere
Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands
Cancer Sci 101:7-15. 2010..As the VEGF pathway also affects the sensitivity of tumor cells to chemotherapeutics, combinations of compounds targeting this pathway and conventional cytotoxics have been explored. This review addresses such combinations... - mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cellsMichiel H Strijbos
Laboratory of Translational Tumorimmunolgy, Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Thromb Haemost 104:318-26. 2010..We conclude that mRNA levels of CD31, CD144, CD146 and vWf in whole blood as detected by real time RT-PCR cannot be used as biomarkers for end-stage endothelial cells such as CEC... - High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancerM P H M Jansen
Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Center, Erasmus Medical Center Rotterdam, Room Be401, PO Box 2040, 3000 CA Rotterdam, The Netherlands
Breast Cancer Res Treat 133:937-47. 2012..Cell cycle regulation is the only overlapping pathway linked to miR-26a and EZH2 levels. Low mRNA levels of EZH2, CCNE1, and CDC2, and high levels of miR-26a are associated with favorable outcome on tamoxifen... - The applicability of mTOR inhibition in solid tumorsI R H M Konings
Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Curr Cancer Drug Targets 9:439-50. 2009..Additionally, potential predictors of outcome to mTOR-inhibition are discussed... - Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspectsMariëtte Hw Kappers
Division of Pharmacology, Vascular and Metabolic Diseases, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
J Hypertens 27:2297-309. 2009..This may lead to the development of more specific angiogenesis inhibitors, better management of their side effects and may potentially provide new insights into the pathogenesis of cardiovascular disease in general... - Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival modelsJ S Vermaat
Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Ann Oncol 21:1472-81. 2010..To improve prognostication, we applied proteomics to identify novel serological proteins associated with overall survival (OS)... - Retroviral vectors for clinical immunogene therapy are stable for up to 9 yearsC H J Lamers
Department of Medical Oncology, Laboratory of Clinical and Tumor Immunology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Cancer Gene Ther 15:268-74. 2008..These data provide evidence that in terms of 'life expectancy' the production and storage of clinical batches of RTVsup for gene therapy warrants the corresponding professional and financial risks... - Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytesC H J Lamers
Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
J Biol Regul Homeost Agents 18:134-40. 2004..Currently, we evaluate this concept in a clinical protocol to treat patients with metastatic renal cell cancer (RCC) using autologous RCC-specific gene-modified T lymphocytes... - Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patientsD Fekkes
Department of Neuroscience, Erasmus MC, The Netherlands
Amino Acids 32:121-6. 2007..The data suggest that therapy with PEG-IFN-alpha results in a marked decrease in the synthesis of NO in melanoma patients... - Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-sC H J Lamers
Unit Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Cytotherapy 8:542-53. 2006..We describe the validation of our clinical protocol for gene transduction and expansion of human T lymphocytes... - Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistanceTon van Agthoven
Department of Pathology, Cancer Genomics Center, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
J Clin Oncol 27:542-9. 2009..Here, we explored whether these BCAR genes provide predictive value for tamoxifen resistance and prognostic information for tumor aggressiveness in breast cancer patients... - Application of prolonged microdialysis sampling in carboplatin-treated cancer patientsInge R H M Konings
Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
Cancer Chemother Pharmacol 64:509-16. 2009..We explored the feasibility of microdialysis in tumor tissue for multiple days in a clinical setting, using carboplatin as model drug... - Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cellsAnieta M Sieuwerts
Department of Medical Oncology, Josephine Nefkens Institute, Cancer Genomics Centre, Rotterdam, The Netherlands
J Natl Cancer Inst 101:61-6. 2009..New tests that include antibodies that specifically recognize normal-like breast tumor cells but not cells of hematopoietic origin are needed... - MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancerF Germán Rodríguez-González
Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute and Cancer Genomics Centre, Dr Molewaterplein 50, Be 4 02 lab 4 35b office, PO Box 2040, 3000 CA Rotterdam, The Netherlands
Breast Cancer Res Treat 127:43-51. 2011..Assessment of tumor levels and connected pathways could be helpful to improve treatment strategies... - External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility studyJaco Kraan
Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
Cytometry B Clin Cytom 80:112-8. 2011..We studied the feasibility of external quality assurance (EQA) of the entire CellSearch procedure from blood draw to interpretation of results in multiple laboratories... - On the origin of (CD105+) circulating endothelial cellsMichiel H Strijbos
Erasmus University Medical Center Daniel den Hoed Cancer, Center Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Thromb Haemost 102:347-51. 2009.... - Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropeniaJessica M van der Bol
Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, 3075 EA Rotterdam, The Netherlands
Oncologist 15:1063-72. 2010..However, these reported associations are inconsistent, and data on patients with solid tumors are lacking. Here, we investigated the effects of MBL2 genotypes on irinotecan-induced febrile neutropenia in patients with solid tumors... - Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levelsMariette H W Kappers
Division of Pharmacology, Vascular and Metabolic Diseases, Department of Internal Medicine, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands
Hypertension 56:675-81. 2010..In conclusion, sunitinib induces a reversible rise in BP in patients and in rats associated with activation of the endothelin-1 system, suppression of the renin-angiotensin system, and generalized microvascular dysfunction... - Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis studyInge R H M Konings
Department of Medical Oncology, Erasmus University Medical Center, Room HE 118, s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands
Cancer Chemother Pharmacol 67:1055-62. 2011..Sampling for measurement of 5-fluorouracil in tumor tissue was performed using microdialysis... - Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146Bianca Mostert
Department of Medical Oncology, Daniel den Hoed Cancer Center and Laboratory of Translational Tumor Immunology, Erasmus MC, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Breast Cancer Res Treat 127:33-41. 2011..CD146+ CTCs are present in the peripheral blood of breast cancer patients with advanced disease. Combined use of anti-CD146 and anti-EpCAM is likely to improve CTC detection in breast cancer patients... - (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitorPaul Hamberg
Erasmus University Medical Center Daniel den Hoed Cancer Center, Department of Medical Oncology, 3008 AE Rotterdam, The Netherlands
Oncologist 15:539-47. 2010..This review summarizes the preclinical and clinical pharmacokinetics and pharmacodynamics of pazopanib, as well as data on clinical activity, that ultimately resulted in its recent approval... - Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effectsMarjolein Bannink
Department of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands
Neuropsychobiology 55:225-31. 2007..The alterations in tryptophan metabolism might underlie the psychiatric side effects during treatment with IFN-alpha... - Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancerBianca Mostert
Department of Medical Oncology, Erasmus Medical Center Josephine Nefkens Institute and Cancer Genomics Centre, 3015 GE Rotterdam, The Netherlands
Cancer Treat Rev 35:463-74. 2009..We have focused on breast cancer as most clinical studies on CTC detection so far have been done in these patients... - Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-alpha therapyDurk Fekkes
Department of Neuroscience, Erasmus MC, Rotterdam, The Netherlands
Amino Acids 37:703-8. 2009.... - Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric statusArthur R Van Gool
Department of Psychiatry, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Psychiatry Clin Neurosci 62:597-602. 2008..In contrast, other catabolites of KYN, such as kynurenic acid (KA), are thought to have neuroprotective properties... - Cells meeting our immunophenotypic criteria of endothelial cells are large plateletsMichiel H Strijbos
Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Cytometry B Clin Cytom 72:86-93. 2007..Blood 2001;97:3658-3661). Here, we set out to confirm the endothelial nature of these cells... - Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivoCor H J Lamers
Laboratory for Clinical and Tumor Immunology, Department of Medical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE, Rotterdam, The Netherlands
Cancer Immunol Immunother 56:1875-83. 2007..Here, we investigate whether or not the in vivo activity of the infused scFv(G250)(+) T cells is reflected by changes of selected immune parameters measured in peripheral blood... - Bleomycin and scuba diving: where is the harm?Ronald de Wit
Erasmus University Medical Centre, Rotterdam, Netherlands
Lancet Oncol 8:954-5. 2007 - Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipatedMarjolein Bannink
Dept of Psychiatry, Erasmus Medical Center, Rotterdam, The Netherlands
Psychosomatics 49:56-63. 2008..The results of this study indicate that IFN-alpha treatment is not suitable as a study model for depression in general... - Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCRAnieta M Sieuwerts
Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus MC, Room BE 400, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
Breast Cancer Res Treat 118:455-68. 2009..Our method allows molecular characterization specific for as little as one CTC, and can be used to expand the understanding of the biology of metastasis and, potentially, to improve patient management... - GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial designJaap Verweij
Erasmus University Medical Center, Daniel den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
Adv Exp Med Biol 610:144-54. 2008 - Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patientsMarjolein Bannink
Department of Psychiatry, Erasmus MC Daniel den Hoed Cancer Center, P O Box 5201, 3008 AE Rotterdam, The Netherlands
Prog Neuropsychopharmacol Biol Psychiatry 29:109-14. 2005..In that case, increased platelet MAO activity reflects an increased number of mitochondria per platelet... - Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancerMaurice P H M Jansen
Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
Breast Cancer Res Treat 116:263-71. 2009..The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in endocrine therapy resistance... - The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?Ferry A L M Eskens
Erasmus University Medical Center, Department of Medical Oncology, Rotterdam, The Netherlands
Eur J Cancer 44:2350-6. 2008..In this review, we address the results of clinical studies upon which bevacizumab's current use is based and discuss some future perspectives... - Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damageMichiel H Strijbos
Erasmus University Medical Center Daniel den Hoed Cancer Center, Groene Hilledijk 301, Rotterdam, The Netherlands
Thromb Haemost 100:642-7. 2008..Higher levels of thrombomodulin and E-selectin were observed in males when compared to females. In conclusion, CEC numbers correlate positively with plasma levels of thrombomodulin... - T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studiesMiriam Coccoris
Erasmus MC Daniel den Hoed Cancer Center, Laboratory of Experimental Tumor immunology, Rotterdam, The Netherlands
Expert Opin Biol Ther 10:547-62. 2010..Introduction of tumour-specific T cell receptors into T cells, termed TCR gene therapy, can provide an alternative for ACT that is more widely applicable and might be extended to other types of cancer... - Circulating endothelial cells in oncology: pitfalls and promisesM H Strijbos
Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
Br J Cancer 98:1731-5. 2008..In this review, we will address the possible clinical applications of CEC detection in oncology, as well as the pitfalls encountered in this process... - Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinomaA R Van Gool
Department of Psychiatry, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
J Interferon Cytokine Res 28:283-6. 2008..As more subtle relationships between PEP activity and psychiatric status could have easily been obscured, a role for PEP in the pathophysiology of IFN-alpha-induced mood disturbance can neither be confirmed nor excluded... - Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine originA W Oosten
Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Sarcoma 2009:348910. 2009..If our observations are confirmed in other series, they would suggest that studies performed in STS patients should not only stratify for histological subtype but also for uterine versus non-uterine LMS and for gender... - Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I studyConstantijne H Mom
Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands
Clin Cancer Res 15:5584-90. 2009.... - Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometryPeter de Bruijn
Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, The Netherlands
J Pharm Biomed Anal 51:934-41. 2010..200 to 50.0ng/ml with the lower limit of quantitation validated at 0.200ng/ml for both sunitinib and SU12662. The within-run and between-run precisions were within 11.7%, while the accuracy ranged from 90.5 to 106.8%... - Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy responseJozien Helleman
Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Clin Cancer Res 14:5555-64. 2008.... - The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator?A Jager
Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
Eur J Cancer 44:175-81. 2008.... - Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yieldC H J Lamers
Laboratory of Clinical and Tumor Immunology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Cytotherapy 10:406-16. 2008..Critical to our successful clinical-scale transductions of patient T cells was the use of Retronectin in combination with Lifecell X-foldtrade mark cell culture bags... - Circulating endothelial cells: a potential parameter of organ damage in sickle cell anemia?Michiel H Strijbos
Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
Blood Cells Mol Dis 43:63-7. 2009..002). No significant correlations between CEC and any other laboratory parameter were detected. In conclusion, CECs could prove to be an important new tool for assessing developing vasculopathy and organ damage in SCD... - Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?Stefan Sleijfer
Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Nat Clin Pract Oncol 2:70-1. 2005 - Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinibPaul Hamberg
J Clin Oncol 24:e30-1. 2006 - Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenonStefan Sleijfer
Onkologie 31:6-8. 2008 - Pulmonary alterations during BEP? Always be aware of BIPStefan Sleijfer
Onkologie 30:291-2. 2007 - Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experienceCor H J Lamers
J Clin Oncol 24:e20-2. 2006 - Potential biomarkers in metastatic gastrointestinal stromal tumorsMichiel H Strijbos
Clin Cancer Res 13:6244. 2007 - Editorial: the long and winding road to better cancer cell-specific therapiesStefan Sleijfer
Oncologist 13:593-5. 2008 - Dose selection in phase I studies: why we should always go for the topStefan Sleijfer
J Clin Oncol 26:1576-8. 2008 - Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-upP G Casali
Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
Ann Oncol 19:ii35-8. 2008 - Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-upP G Casali
Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
Ann Oncol 19:ii89-93. 2008